ALNYLAM PHARMACEUTICALS, INC. (ALNY)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$1,658.8M
Cash & Equivalents
$524.1M
Quarterly Burn Rate
$39,888M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (4 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
VUTRISIRAN SODIUM
AMVUTTRA |
APPROVED | Acute Hepatic Porphyria, Acute Hepatic Porphyria (AHP), Acute Intermittent Porphyria, Acute Intermittent Porphyria (AIP), Acute Porphyria, Advanced Hepatocellular Carcinoma, AGT, ALA Dehydratase Deficient Porphyria (ADP), Alzheimer's Disease, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Amyloidosis, Amyloidosis, Familial, Amyloidosis, Hereditary, Amyloidosis, Hereditary, Transthyretin-Related, Antitrypsin Deficiency Liver Disease, Asymptomatic Carrier State, ATTR Amyloidosis, ATTR Amyloidosis With Cardiomyopathy, Atypical Hemolytic Uremic Syndrome, Berger Disease, Cardiomyopathies, Cardiovascular Disease, Cardiovascular Risk Factor, Cerebral Amyloid Angiopathy, Chronic Hepatitis B, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Disease Requiring Chronic Dialysis, Down Syndrome-Associated Alzheimer's Disease (DS-AD), Early-Onset Alzheimer Disease, Elevated LDL-Cholesterol (LDL-C), Elevated Urinary Oxalate Levels, Familial Amyloid Neuropathies, Familial Amyloid Polyneuropathies, Fami |
|
GIVOSIRAN SODIUM
GIVLAARI |
APPROVED | — |
|
LUMASIRAN SODIUM
OXLUMO |
APPROVED | — |
|
PATISIRAN SODIUM
ONPATTRO |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-29 | Phase1 Readout | — |
| 2027-04-27 | Phase2 Readout | — |
| 2027-05-28 | Phase2 Readout | — |
| 2027-06-30 | Phase2 Readout | — |
Active Clinical Trials (26)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04883905 | ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | OTHER | Recruiting | 150 |
| NCT04982393 | BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) | OTHER | Active Not Recruiting | 207 |
| NCT05577819 | Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF | OTHER | Recruiting | 515 |
| NCT05040373 | Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program | OTHER | Recruiting | 10 |
| NCT04561518 | ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) | OTHER | Recruiting | 1,500 |
| NCT06360289 | Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR... | OTHER | Active Not Recruiting | 346 |
| NCT07358078 | DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting | OTHER | Recruiting | 2,000 |
| NCT07223203 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos... | PHASE3 | Recruiting | 125 |
| NCT07052903 | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | PHASE3 | Recruiting | 1,250 |
| NCT04153149 | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | PHASE3 | Active Not Recruiting | 655 |
| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease o... | PHASE3 | Recruiting | 11,000 |
| NCT06679946 | A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | PHASE3 | Enrolling By Invitation | 700 |
| NCT07465224 | A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus | PHASE2 | Recruiting | 40 |
| NCT06225544 | Lumasiran in Hyperoxalaemic Patients on Haemodialysis | PHASE2 | Recruiting | 50 |
| NCT06393712 | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy | PHASE2 | Recruiting | 200 |
| NCT07463846 | A Study to Evaluate ALN-2232 in Participants With Obesity | PHASE2 | Recruiting | 156 |
| NCT06659640 | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | PHASE2 | Recruiting | 120 |
| NCT06845202 | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | PHASE2 | Recruiting | 144 |
| NCT07553442 | A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran | PHASE2 | Recruiting | 93 |
| NCT06585449 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | PHASE1 | Recruiting | 66 |
| NCT07624071 | A Study to Evaluate ALN-6222 in Participants With Obesity | PHASE1 | Recruiting | 88 |
| NCT07295717 | A Study to Evaluate ALN-4285 in Adult Healthy Volunteers | PHASE1 | Recruiting | 76 |
| NCT07214727 | A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease | PHASE1 | Recruiting | 50 |
| NCT06600321 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | PHASE1 | Recruiting | 158 |
| NCT07535606 | A Study to Evaluate ALN-4915 in Adult Healthy Volunteers | PHASE1 | Recruiting | 44 |
| NCT05231785 | A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD | PHASE1 | Recruiting | 60 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.